Schizophrenia Trial, Recruiting NCT01392885 Sponsor: BC Mental Health and Addictions Research Institute Condition: Schizophrenia
Back to Schizophrenia

Schizophrenia Trial, Recruiting

NCT01392885
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 45 years old
  • People who are able to give written consent in English
  • People who are currently taking prescribed medications may still be eligible
  • People who have been diagnosed with schizophrenia or schizoaffective disorder (as defined by DSM-IV criteria)
  • People with normal vision, either naturally or with corrective lenses such as glasses or contacts
  • People who are physically able to participate in a regular exercise program

Who may not be able to join:

  • People who have a history of organic brain conditions, such as dementia, severe head injury, or developmental disorders including autism, intellectual disability, or Down's Syndrome
  • People who have been diagnosed with a substance dependence disorder in the past 12 months (not including tobacco)
  • People who have any other psychiatric diagnosis (beyond schizophrenia or schizoaffective disorder) as defined by DSM-IV criteria
  • People who have a history of chest pain (angina), heart attack, or mini-strokes (transient ischemic attacks)
  • People who are unable to move around independently or who use a limb prosthesis
  • People who have a history of a severe head injury that caused loss of consciousness for more than 5 minutes
  • People who cannot safely undergo brain imaging scans — for example, those with metal implants, non-removable braces, severe claustrophobia, current pregnancy, or surgery within the past 6 months
  • People who are already participating in a regular exercise program

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Donna J Lang, PhD, University of British Columbia, Dept. of Radiology

Phone: 604-875-2000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
BC Mental Health and Addictions Research Institute
Registry
ClinicalTrials.gov
Start date
1 July 2011
Est. completion
1 June 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Increase hippocampal volume with aerobic training in schizophrenic and healthy volunteers.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov